Walleye Capital’s ANI Pharmaceuticals ANIP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
– Sell
-1,200
Closed -$74K – 907
2019
Q4
$74K Sell
1,200
-1,900
-61% -$126K ﹤0.01% 1428
2019
Q3
$226K Buy
+3,100
New +$232K 0.01% 1143
2019
Q2
– Sell
-2,000
Closed -$141K – 1712
2019
Q1
$141K Buy
+2,000
New +$118K 0.02% 907

Other funds holding ANIP

Walleye Capital's ANIP Position: Q3 2026 in Review

Walleye Capital reduced its ANI Pharmaceuticals (ANIP) stake by 82% in Q3 2026, selling an estimated $6.69M and leaving 19,245 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3156.

Walleye Capital first reported a position in ANIP in Q1 2019 and has held it in 15 quarters since. The position peaked at $19.8M in Q3 2025. 289 funds tracked by Wall St. Rank hold ANIP as of Q3 2026.

  • Walleye Capital held 19,245 shares of ANI Pharmaceuticals worth $1.4M as of Q3 2026.
  • Walleye Capital sold 86,867 ANI Pharmaceuticals shares in Q3 2026, an estimated $6.69M.
  • ANI Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #3156 holding.
  • Walleye Capital first reported a position in ANI Pharmaceuticals in Q1 2019 and has held it in 15 quarters since.
  • Walleye Capital's ANI Pharmaceuticals position peaked at $19.8M in Q3 2025.
  • 289 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.